The Lake Success office of Long Island neurosurgeon practice has been selected for a nationwide clinical trial.
NSPC Brain & Spine Surgery will serve as one of several study sites for a nationwide clinical trial of a drug to treat the pain of trigeminal neuralgia, or TN, a neuropathic facial pain condition that experts say produces sudden, excruciating pain in the jaw or cheek area on one side of an affected person’s face.
The clinical trial will evaluate the safety and efficacy of Rimegepant, a drug manufactured by Biohaven Pharmaceuticals, comparing the medication to a placebo for adults, 18 years or older, said Dr. Jeffrey Brown. Brown a senior partner and attending neurosurgeon at NSPC and also serves as the Facial Pain Association medical advisory board national chairman.
Rimegepant “has been shown to be safe and efficacious for the treatment of migraine headaches,” Brown said in a statement, noting that the drug is approved by the Food & Drug Administration for this condition.
“Trigeminal neuralgia is a potentially new use for this medication, which works by a different mechanism than the established drugs currently in use and may be effective in treating the pain of TN,” he said.
The study is open to patients, “with poorly controlled trigeminal neuralgia as determined by careful evaluation,” he said. “It will be double blinded and will take approximately seven to nine weeks to complete, with an opportunity to continue for an additional 12 weeks. Participants may be able to continue a stabilized dosage of their current medications.”
Patients in the study will be randomly assigned either Rimegepant or a placebo.
Screening evaluations and an MRI may be required prior to enrollment in the study. A series of pain scale evaluations, as well as blood tests, will be completed during the trial to assure the safety of participants
More information about the study is available here.